Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification
Shanshan Jia,Hua Luo,Xinkui Liu,Xiaotian Fan,Zhihong Huang,Shan Lu,Liangliang Shen,Siyu Guo,Yingying Liu,Zhenzhong Wang,Liang Cao,Zeyu Cao,Xinzhuang Zhang,Wei Zhou,Jingyuan Zhang,Jialin Li,Jiarui Wu,Wei Xiao
DOI: https://doi.org/10.1016/j.jep.2021.113871
IF: 5.195
2021-06-01
Journal of Ethnopharmacology
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Ethnopharmacological relevance</h3><p>Reduning injection (RDNI) is a patented Traditional Chinese medicine that contains three Chinese herbal medicines, respectively are the dry aboveground part of <em>Artemisia annua L.</em>, the flower of <em>Lonicera japonica Thunb.</em>, and the fruit <em>Gardenia jasminoides J.Ellis.</em> RDNI has been recommended for treating Coronavirus Disease 2019 (COVID-19) in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan".</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aim of the study</h3><p>To elucidate and verify the underlying mechanisms of RDNI for the treatment of COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>This study firstly performed anti-SARS-CoV-2 experiments in Vero E6 cells. Then, network pharmacology combined with molecular docking was adopted to explore the potential mechanisms of RDNI in the treatment for COVID-19. After that, western blot and a cytokine chip were used to validate the predictive results.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>We concluded that half toxic concentration of drug CC50 (dilution ratio) =1:1280, CC50=2.031 mg crude drugs/mL (0.047 mg solid content/mL) and half effective concentration of drug (EC50) (diluted multiples) =1:25140.3, EC50=103.420μg crude drugs/mL (2.405μg solid content/mL). We found that RDNI can mainly regulate targets like carbonic anhydrases (CAs), matrix metallopeptidases (MMPs) and pathways like PI3K/AKT, MAPK, Forkhead box O s and T cell receptor signaling pathways to reduce lung damage. We verified that RDNI could effectively inhibit the overexpression of MAPKs, PKC and p65 nuclear factor-κB. The injection could also affect cytokine levels, reduce inflammation and display antipyretic activity.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>RDNI can regulate ACE2, Mpro and PLP in COVID-19. The underlying mechanisms of RDNI in the treatment for COVID-19 may be related to the modulation of the cytokine levels and inflammation and its antipyretic activity by regulating the expression of MAPKs, PKC and p65 nuclear factor NF-κB.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences